Alemtuzumab slows brain volume loss over 5 years in patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years: CARE MS I and II extension study

作者:Barkhof F; Cohen J A; Coles A J; Compston D A S; Filippi M; Fox E J; Giovannoni G; Hartung H P; Havrdova E; Schippling S; Selmaj K W; Margolin D H; Thangavelu K; Panzara M A; Arnold D L
来源:31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), 2015-10-07 to 2015-10-10.
  • 出版日期2015-9